How many cadavers' pituitary gland would be required to extract 1 unit of GH?
Reading File
Searching the Web
how many cadaver pituitary glands required to extract 1 unit growth hormone
Finding Sources
Reading File
Finding Sources
Finding Sources
Searching the Web
cadaveric pituitary glands "80 pituitary" OR "100 pituitary" growth hormone 1 unit extraction history
Reading Web Page
how many pituitary glands per unit of growth hormone cadaver extraction
Now I have solid sourced information. Here is the complete answer:
Cadaveric Pituitary Glands Required to Extract 1 Unit of GH
The classic answer cited in endocrinology and biochemistry teaching is approximately 80 cadaveric pituitary glands per 1 IU (International Unit) of GH. This figure reflects the extremely low yield of the extraction process and explains why cadaver-derived GH (pit-GH) was always in critically short supply.
Why so many glands?
- Each human pituitary gland weighs only about 0.5-1 g and contains a very small amount of GH.
- The early extraction methods (the Raben method using hot glacial acetic acid, or the Wilhelmi method using freeze/column chromatography) were inefficient and resulted in significant hormone loss at each purification step.
- Only a fraction of the stored GH could be recovered in biologically active, purified form.
Scale of the program in context
The US National Pituitary Agency (later the National Hormone and Pituitary Program, NHPP) pooled glands on a massive scale. According to the CDC's 1985 MMWR report, each treatment batch was derived from a pool of approximately 16,000 cadaver pituitary glands, underscoring just how many donors were needed to treat even a single patient for one year.
Between 1963 and 1985, roughly 27,000 children worldwide (about 7,700 in the US alone) were treated with pit-GH before the program was halted - all requiring continuous pooled collections from tens of thousands of cadavers per year.
Why it ended
In 1985, pit-GH was withdrawn from the market after it was found to transmit Creutzfeldt-Jakob disease (CJD) via contaminating prions from donor brains. Because batches were pooled from thousands of glands, a single infected donor could expose every patient in that batch. Over 50 patients who received pit-GH eventually developed CJD.
Biosynthetic recombinant GH (somatropin, produced in E. coli) replaced pit-GH in 1985, making cadaveric extraction obsolete.
Summary
| Parameter | Value |
|---|---|
| Glands per 1 IU of GH (classic figure) | ~80 cadaver pituitary glands |
| Glands per treatment batch (NHPP) | ~16,000 |
| Era of cadaveric GH use | 1958-1985 |
| Replaced by | Recombinant somatropin (1985) |
Sources: CDC MMWR 1985; PMC History of GH Therapy; Laron Z, "The Era of Cadaveric Pituitary Extracted Human Growth Hormone" (PMID 30378778); Basic Medical Biochemistry 6e (Lieberman & Ricer).
Now tell me something about recombinant technology for getting the same hormone. In short.
Finding Sources
Reading File
Reading File
Here is a short summary of recombinant GH technology:
Recombinant Human Growth Hormone (rhGH / Somatropin)
How it is made: The human GH gene (coding for a 191-amino-acid polypeptide) is inserted into Escherichia coli using recombinant DNA technology. The bacteria express the protein in large, essentially unlimited quantities. The resulting product - somatropin - has an identical 191-amino-acid sequence to the predominant native human GH, including the same two sulfhydryl bridges. It replaced cadaveric pit-GH in 1985.
Key advantages over cadaveric GH:
- Unlimited supply - no donor dependence
- No prion contamination risk (eliminated CJD transmission)
- Consistent purity and potency between batches
How it works (pharmacology): GH binds cell-surface receptors of the JAK/STAT cytokine receptor superfamily. A single GH molecule dimerizes two receptors, activating JAK tyrosine kinases and STAT signaling. Most growth-promoting effects are mediated indirectly through IGF-1 (largely produced by the liver), which stimulates longitudinal bone growth until epiphyseal plates fuse.
Administration: Subcutaneous injection, classically 6-7 times per week. Newer long-acting derivatives (e.g., lonapegsomatropin, modified with an albumin-binding moiety or a transiently linked carrier) allow once-weekly dosing with comparable efficacy.
Therapeutic uses:
- GH deficiency in children (pituitary dwarfism)
- Growth failure (Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency)
- GH deficiency in adults (post-surgical, radiation, trauma)
- HIV-associated wasting/cachexia
Adverse effects: Injection-site pain, edema, arthralgias, myalgias, mild hyperglycemia/insulin resistance. Contraindicated in patients with closed epiphyses, diabetic retinopathy, or obese Prader-Willi patients.
- Lippincott Pharmacology 7e, p. 769-770
- Katzung Basic & Clinical Pharmacology 16e, p. 1047
This is a shared conversation. Sign in to Orris to start your own chat.